Variations of the proprotein convertase subtilisin/kexin type 9 gene in coronary artery disease

被引:6
|
作者
Chiang, Shih-Min [1 ]
Yang, Yi-Sun [1 ,2 ,3 ]
Yang, Shun-Fa [1 ,4 ]
Tsai, Chin-Feng [5 ]
Ueng, Kwo-Chnag [3 ,5 ]
机构
[1] Chung Shan Med Univ, Inst Med, Taichung, Taiwan
[2] Chung Shan Med Univ Hosp, Div Endocrinol & Metab, Dept Internal Med, Taichung, Taiwan
[3] Chung Shan Med Univ, Sch Med, Taichung, Taiwan
[4] Chung Shan Med Univ Hosp, Dept Med Res, Taichung, Taiwan
[5] Chung Shan Med Univ Hosp, Div Cardiol, Dept Internal Med, 110,Sec1,Jianguo N Rd, Taichung 40201, Taiwan
关键词
Proprotein Convertase Subtilisin/Kexin Type 9; coronary artery disease; diabetes; polymorphisms; Taiwanese; genotyping; LIPOPROTEIN CHOLESTEROL LEVELS; PCSK9; GENE; SEQUENCE VARIATIONS; E670G POLYMORPHISM; RISK; MUTATIONS; SEVERITY; LDL;
D O I
10.1177/0300060519839519
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective: Coronary artery disease (CAD) is the principal cause of mortality and morbidity worldwide. Studies have provided controversial results regarding whether variations in the proprotein convertase subtilisin/kexin type 9 gene (PCSK9) are risk factors for CAD. In this study, we evaluated the risk factors associated with PSCK9 genotypes and CAD in the Taiwanese population. Methods: A total of 501 patients diagnosed with CAD by angiography and 334 CAD-free controls were recruited. Two single nucleotide polymorphisms of PSCK9 (rs505151 and rs529787) were genotyped. Results: The prevalence of a positive family history for CAD was significantly higher in individuals carrying the AG+GG genotype of the PSCK9 rs505151 polymorphism. Among CAD patients with a positive family history, the prevalence of diabetes mellitus was significantly higher in those carrying the AG+GG genotype of the PSCK9 rs505151 polymorphism (73.3%) than in those carrying the AA genotype (39.2%). Conclusion: In CAD patients, the AG genotype of PSCK9 rs505151 is associated with diabetes and a positive family history of CAD.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9
    Miao, Ji
    Manthena, Praveen V.
    Haas, Mary E.
    Ling, Alisha V.
    Shin, Dong-Ju
    Graham, Mark J.
    Crooke, Rosanne M.
    Liu, Jingwen
    Biddinger, Sudha B.
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2015, 35 (07) : 1589 - 1596
  • [22] Targeting proprotein convertase subtilisin/kexin type 9 in mice and monkeys
    Wang, Ya
    Ma, Murong
    Wang, Jian-An
    Daugherty, Alan
    Lu, Hong S.
    [J]. CURRENT OPINION IN LIPIDOLOGY, 2019, 30 (02) : 154 - 155
  • [23] Potential of Proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics
    Stein, Evan A.
    Swergold, Gary D.
    [J]. CURRENT ATHEROSCLEROSIS REPORTS, 2013, 15 (03)
  • [24] Natural Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Review
    Singh, Sonia
    Sharma, Himanshu
    Ramankutty, Raghavan
    Ramaswamy, Sarada
    Agrawal, Nitin
    [J]. COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2023, 26 (15) : 2668 - 2678
  • [25] Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
    Shapiro, Michael D.
    Miles, Joshua
    Tavori, Hagai
    Fazio, Sergio
    [J]. ANNALS OF INTERNAL MEDICINE, 2018, 168 (05) : 376 - 379
  • [26] A novel splicing variant of proprotein convertase subtilisin/kexin type 9
    Schmidt, Robert J.
    Zhang, Youyan
    Zhao, Yang
    Qian, Yue-Wei
    Wang, He
    Lin, Aimin
    Ehsani, Mariam E.
    Yu, Xiaohong
    Wang, Guoming
    Singh, Jaipal
    Su, Eric W.
    Li, Shuyu
    Konrad, Robert J.
    Cao, Guoqing
    [J]. DNA AND CELL BIOLOGY, 2008, 27 (04) : 183 - 189
  • [27] Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors
    Avci, Ahmet
    Demir, Kenan
    Altunkeser, Bulent Behlul
    [J]. TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2014, 42 : 56 - 67
  • [28] Proprotein convertase subtilisin/kexin type 9 inhibition as the next statin?
    Rakipovski, Gunaj
    Hovingh, G. Kees
    Nyberg, Michael
    [J]. CURRENT OPINION IN LIPIDOLOGY, 2020, 31 (06) : 340 - 346
  • [29] Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?
    Filippatos, Theodosios D.
    Christopoulou, Eliza C.
    Elisaf, Moses S.
    [J]. CURRENT OPINION IN LIPIDOLOGY, 2018, 29 (04) : 333 - 339
  • [30] Proprotein Convertase Subtilisin/kexin Type 9 Inhibition in Cardiovascular Prevention
    Ali, Ali
    Costanzo, Pierluigi
    Hoye, Angela
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (04) : 442 - 450